ArticleScientific reports2025
In vitro, in silico, and DFT evaluation of antimicrobial imidazole derivatives with insights into mechanism of action.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Imidazole Scaffolds against Staphylococcus aureus and MRSA: a medicinal chemistry review.Molecular diversity · 2026Review
- Halogen-tuned tripodal Schiff base ligands: synthesis, antibacterial activity, and DFT-guided mechanistic insights.RSC advances · 2026Article
- Pharmacological potential of the marine peptide cyclo(L-phenylalanyl-L-prolyl) against both multidrug-resistant, gram-negative Acinetobacter baumannii and gram-positive Staphylococcus aureus: structure - activity relationship, computational and experimental studies.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Recent Progress in the Sustainable Synthesis of Imidazole Derivatives: Advances in Multicomponent Reactions, Catalysis, and Green Chemistry.Molecules (Basel, Switzerland) · 2026Review
- Potent LeuBAT inhibitors designed in silico as next-generation duloxetine analogs for enhanced major depressive disorder treatment.Scientific reports · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, three imidazole derivatives : 2,4,5-triphenyl-1-(4-(phenyldiazenyl)phenyl)-1 H-imidazole (N1), 2-(4-chlorophenyl)-4,5-diphenyl-1-(4-(phenyldiazenyl)phenyl)-1 H-imidazole (N2), and 2-(2,4-dichlorophenyl)-4,5-diphenyl-1-(4-(phenyldiazenyl)phenyl)phenyl)-1 H-imidazole (N3), which were prepared using N-methyl-2-pyrrolidone hydrogen sulfate ionic liquid as a catalyst, were selected for detailed evaluation. The antimicrobial activities of these compounds were assessed against a panel of pathogenic microorganisms, including Gram-positive bacteria (Staphylococcus aureus, Bacillus anthracoides), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae), and the fungal strain Candida albicans. The Density Functional Theory (DFT) results showed that the N3 molecule exhibited the highest stability with the largest ΔEgap (2.9546 eV) and chemical hardness, while N1 showed the highest reactivity. Frontier molecular orbital (FMO) and electrostatic potential (ESP) analyses revealed that the HOMO orbitals are delocalized over the imidazole ring and neighboring aromatic fragments, and the LUMO orbitals are spread over the phenyldiazenyl phenyl fragments. A comparative analysis suggests that while N3 is the most chemically stable, N2 demonstrates the highest potential for biological activity, consistent with experimental antimicrobial results. Both in-vitro and in-silico results revealed that the N2 molecule exhibits superior biological activity compared to N1 and N3. Molecular docking studies of N2 were performed with its target protein to explore its binding interactions with several amino acid residues, elucidating its potential antioxidant mechanism. Docking results revealed that all ligands exhibit strong binding affinities, with N1 showing the highest MolDock score and N2 demonstrating strong specificity through key hydrogen bonding and π-interactions. Molecular dynamics simulations, including RMSD, RMSF, radius of gyration (Rg), solvent-accessible surface area (SASA), and principal component analysis (PCA), further confirmed the structural stability and dynamic behavior of the protein-ligand complexes. MMPBSA binding free energy calculations indicated that N2@1AI9 forms the most stable complex, primarily driven by favorable van der Waals and electrostatic interactions. In silico ADMET analysis suggests all compounds, particularly the lead compound N2, face challenges with high lipophilicity, low solubility, and predicted drug-drug interaction risk (CYP2C19 inhibition for all; CYP3A4 and P-gp substrate for N2), yet their lack of BBB permeation supports their further development, especially for topical or intravenous use. Overall, the results suggest that N2 is a promising candidate for further development as a potential antimicrobial anti-fungal agent targeting the ergosterol biosynthesis pathway in Candida albicans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.